Published Abstracts and Manuscripts. Updated: December Published Manuscripts 2003 Present
|
|
- Andra Perkins
- 6 years ago
- Views:
Transcription
1 Published Abstracts and Manuscripts Updated: December 2013 Published Manuscripts 2003 Present Updated: December 2013
2 Published Manuscripts 2013 Greenberg JD, Spruill TM, Shan Y, Reed G, Kremer JM, Potter J, Yazici Y, Ogedegbe G, Harrold LR. Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med Dec;126(12): doi: /j.amjmed Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Greenberg JD. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis Dec 2. doi: /annrheumdis [Epub ahead of print] Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Hochberg MC, Reed G, Tsao P, Greenberg JD. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Seminars in arthritis and rheumatism 2013 doi: /j.semarthrit [Epub ahead of print] Labitigan M, Bahce-Altuntas A, Kremer JM, Reed G, Greenberg JD, Jordan N, Putterman C, Broder A. Higher rates and clustering of abnormal lipids, obesity, and diabetes in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) Oct 7. doi: /acr [Epub ahead of print] McAllister K, Yarwood A, Bowes J, Orozco G, Viatte S, Diogo D, Hocking LJ, Steer S, Wordsworth P, Wilson AG, Morgan AW; UK Rheumatoid Arthritis Genetics Consortium; Rheumatoid Arthritis Consortium International, Kremer J, Pappas D, Gregersen P, Klareskog L, Plenge R, Barton A, Greenberg J, Worthington J, Eyre S. Meta-analysis identifies BACH2 and RAD51B as rheumatoid arthritis susceptibility loci. Arthritis Rheum 2013 Sep 10. doi: /art.38183[Epub ahead of print] Yarwood A, Han B, Raychaudhuri S, Bowes J, Lunt M, Pappas DA, Kremer J, Greenberg JD, Plenge R; Rheumatoid Arthritis Consortium International (RACI), Worthington J, Barton A, Eyre S. A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Ann Rheum Dis Oct 3. [Epub ahead of print] Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Greenberg JD. The Comparative Effectiveness of Abatacept versus Anti-Tumor Necrosis Factor Switching for Rheumatoid Arthritis Patients Previously Treated with an Anti-Tumor Necrosis Factor. Ann Rheum Dis Dec 2. doi: /annrheumdis [Epub ahead of print] Curtis JR, Shan Y, Harrold L Zhang J, Greenber JD, Reed GW. Patient perspectives on achieving T2T goals: A critical examination of patient reported outcomes. Arthritis care & research 2013;65(10): doi: /acr Published Online First: 5 June 2013 Dewitt, EM, Li Y, Curtis JR, Glick HA, Greenberg JD, Anstrom KJ, Kremer JM, Reed G, Schulman KA, Reed SD. Comparative Effectiveness of Nonbiologic versus Biologic Disease Modifying
3 Antirheumatic Drugs for Rheumatoid Arthritis. The Journal of rheumatology 2013;40(2): doi: /jrheum J Diogo D, Kurreeman F, Stahl EA, Liao KP, Gupta N, Greenberg JD, Rivas MA, Hickey B, Flannick J, Thomson B, Guiducci C, Ripke S, Adzhubev I, Barton A, Kremer JM, Aldfredsson L; Consortium of Rheumatology Researchers of North America; Rheumatoid Arthritis Consortium International, Sunyaev S, Martin J, Zhernakova A, Bowes J, Eyre S, Siminovitch KA, Gregersen PK, Worthington J, Klareskog L, Padyukov L, Raychaudhuri S, Plenge RM. Rare, Low-Frequency, and Common Varients in the Protein-Coding Sequence of Biological Candidate Genes from GWASs Contribute to Risk of Rheumatoid Arthritis. Am J Hum Genet Jan 10;92(1): doi: /j.ajhg Epub 2012 Dec 20. Sarsour K, Greenberg JD, Johnston JA, Nelson DR, O Brien LA, Oddoux C, Ostrer H, Pearlman A, Reed G. The Role of the FcGRIIIa Polymorphism in Modifying the Association Between Treatment and Outcome in Patients with Rheumatoid Arthritis Treated with Rituximab Versus TNF-α antagonist therapies. Clin Exp Rheumatol Mar- Apr 3; 31(2): Epub 2013 Jan Pappas DA, Oh C, Plenge RM, Kremer JM, Greenberg JD. Association of Rheumatoid Arthritis Risk Alleles with Response to Anti-TNF Biologics: Results from the CORRONA Registry and Meta-analysis. Inflammation. Inflammation 2013;36(2): doi: /s [Epub ahead of print] PubMed PMID: Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM; CORRONA Investigators. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis Jul;71(7): Epub 2012 Jan 30. PubMed PMID: Jawaheer D, Messing S, Reed G, Ranganath VK, Kremer JM, Louie JS, Khanna D, Greenberg JD, Furst DE. Significance of sex in achieving sustained remission in the Consortium of Rheumatology Researchers of North America cohort of rheumatoid arthritis patients Arthritis care & research 2012;64(12): doi: /acr PubMed PMID: Fisher MC, Hochberg MC, El-Taha M, Kremer JM, Peng C, Greenberg JD; CORRONA Investigators. Smoking, smoking cessation, and disease activity in a large cohort of patients with rheumatoid arthritis. J Rheumatol May;39(5): Epub 2012 Mar 15. PubMed PMID: Fisher MC, Furer V, Hochberg MC, Greenberg JD, Kremer JM, Curtis JR,Reed G, Harrold L, Solomon DH. Malignancy validation in a United States registry of rheumatoid arthritis patients. BMC Musculoskelet Disord May 31;13:85. Harrold LR, Harrington JT, Curtis JR, Furst DE, Bentley MJ, Shan Y, Reed G, Kremer J, Greenberg JD. Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. Arthritis Rheum Mar;64(3): doi: /art PubMed PMID: ; PubMed
4 Central PMCID: PMC Solomon DH, Mercer E, Kavanaugh A. Observational Studies on the Risk of Cancer Associated With Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis. Arthritis Rheum January; 64 (1): DOI /art Anandarajah AP, El-Taha M, Peng C, Reed G, Greenberg JD, Ritchlin CT. Association between focal erosions and generalized bone loss in psoriatic arthritis. Ann Rheum Dis Jul;70(7): Epub 2011 Feb 16. Au K, Reed GW, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis May;70(5): Epub 2011 Feb 2. Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, Greenberg JD. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the consortium of rheumatology researchers of North America registry. Arthritis Care Res (Hoboken) Jun;63(6): Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed GW, Tsao P, Farkouh ME, Nasir A, Setoguchi S, Solomon DH. Tumor necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis Apr;70(4): Epub 2010 Nov 24. Zhang J, Shan Y, Reed G, Kremer J, Greenberg JD, Baumgartner S, Curtis JR: Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. Arthritis care & research 2011, 63(12): Reddy S, Anandarajah A, Fisher M, Mease P, Greenberg J, Kremer J, Reed G, Chen R, Messing S, Kaukenien, K, Ritchlin CT. Comparative analysis of disease activity measures using biologic agents, BMI, Radiographic Features, and Bone Density in Psoriatic Arthritis and Rheumatoid Arthritis Patients Followed in a Large US Disease Registry. Journal of Rheumatology Dec; 37(12): Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed R, Calabrese L, Hooper M, Baumgertner S, and Furst D. Risk of elevated liver enzymes associated with TNF inhibitor utilization in patients with rheumatoid arthritis. Ann Rheum Dis Sep; 69(9): Curtis JR, Jain A, Askling J, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Seminars in arthritis and rheumatism. Aug 2010;40(1):2-14 e11.
5 Bentley MJ, Greenberg JD, Reed GW. A modified rheumatoid arthritis disease activity score without acute-phase reactants (mdas28) for epidemiological research. J Rheumatology Aug 1;37(8): Solomon DH, Kremer JM, Curtis JR, Hochberg M, Reed G, Tsao P, Farkouh M, Setoguch S, and Greenberg JD. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional Risk Factors Versus Markers of Rheumatoid Arthritis Severity. Ann Rheum Dis Nov;69(11): Epub 2010 May 5. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, Hochberg M. Association of methotrexate and tumor necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis Feb;69(2): Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH. Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res Jan 15;62(1): Curtis JR, Beukelman T, Onofrei A, Strand V, Greenberg JD, Reed G, Kremer JM. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Annals of Rheumatic Disease 2010 Jan; 69(1): Kremer JM, Greenberg JD. Interpreting registry derived drug studies: does societal context matter? Arthritis Rheum Nov; 60(11): Curtis JR, Patkar NM, Jain A, Greenberg J, Solomon DH. The validity of physician-reported hospitalized infections in an observational U.S. arthritis registry. Rheumatology (Oxford) 2009 October; 48(10): Lee SJ, Chang H, Yazici Y, Greenberg JD, Kremer JM, Kavanaugh A. Utilization trends of tumor necrosis factor inhibitors among rheumatoid arthritis patients in a United States observational cohort study. J Rheumatol Aug; 36(8): Furst D, Chang H, Greenberg J, Ranganath V, Reed G, Ozturk Z, Kremer JM. Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: Evidence from the CORRONA registry. Clin Exp Rheumatol Jul-Aug;27(4): Greenberg JD, Fisher MC, Kremer JM, Chang H, Rosenstein ED, Kishimoto M, Lee S, Yazici Y, Kavanaugh A, Abramson SB. The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Clin Exp Rheumatol May-Jun; 27(3): Greenberg JD, Harrold LR, Bentley MJ, Kremer JM, Reed G. Strand V. Evaluation of composite measures of treatment response without acute phase reactants in patients with rheumatoid arthritis. Rheumatology (Oxford) June; 48(6):686-90
6 Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol Jun;15(4): Aizer J, Reed G, Onofrei A, Harrison MJ. Predictors of bone density testing in patients with rheumatoid arthritis. Rheumatology international. Jun 2009;29(8): Ranganath VK, Paulus HE, Onofrei A, Khanna D, Reed G, Elashoff DA, Kremer JM, Furst DE. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database. J Rheumatol Oct;35(10): Greenberg JD, Kishimoto M, Strand V, Cohen SB, Olenginski TP, Harrington JT, Kafka SP, Reed G, Kremer JM. TNF antagonist responsiveness in a United States rheumatoid arthritis cohort. Am J Med June;121(6): Kremer JM, Gibofsky A, Greenberg JD. The role of drug and disease registries in rheumatic disease epidemiology. Current Opinion in Rheumatology March;20(2): Tutuncu Z, Reed G, Kremer JM, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis Sep;65(9): Greenberg JD, Bingham CO, Abramson SB, Reed G, Kishimoto M, Hinkle K, Kremer JM. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Arthritis Rheum (Arthritis Care and Research), Aug 2006;55(4): Kremer JM. The CORRONA Database. Autoimmun Rev Jan;5(1): Kremer JM. The CORRONA Database. Ann Rheum Dis Nov;64 Suppl 4:iv Kremer JM. The CORRONA Database. Clin Exp Rheumatol Sep-Oct;23(5 Suppl 39):S Greenberg JD, Bingham CO, Abramson SB, Reed G, Seibaldt R, Kremer JM. Effect of cardiovascular comorbidities and concomitant aspirin use onselection of cyclooxgenase inhibitor among rheumatologists. Arthritis Rheum (Arthritis Care and Research), 2005 Feb;53:
7 Sebaldt RJ, Kremer JM. CANDOO and CANOAR, CORRONA and more: advancing therapeutics through layered-in clinical data collection and feedback at the point of care. The Journal of rheumatology. Nov 2003;30(11):
Joel Kremer, MD, President and Chief Executive Officer
CORRONA News Winter 2014 In This Issue: Joel s Corner pg 1 Launch of Psoriasis Registry with the NPF The List of CORRONA Publications, Presentations and Posters is More than Just a List pg 2 pg 3 RA Registry
More informationAssociation of Rheumatoid Arthritis Risk Alleles with Response to Anti-TNF Biologics: Results from the CORRONA Registry and Meta-analysis
Inflammation ( # 2012) DOI: 10.1007/s10753-012-9544-4 Association of Rheumatoid Arthritis Risk Alleles with Response to Anti-TNF Biologics: Results from the CORRONA Registry and Meta-analysis Dimitrios
More informationIdentifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations
University of Massachusetts Medical School escholarship@umms Open Access Articles Open Access Publications by UMMS Authors 4-26-2016 Identifying factors associated with concordance with the American College
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationJoel Kremer, MD, President and Chief Executive Officer
CORRONA News Fall 2013 In This Issue: Joel s Corner...pg 1 Gout Update...pg 2 SpA/PsA Registry has Taken Off...pg 2 Treat to Target Enrollment Complete...pg 3 CERTAIN Fall Update...pg 3 TAE Talk...pg 5
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationTITLE: Safety of Leflunomide and Methotrexate as Combination Therapy for Rheumatoid Arthritis: A Review of the Clinical Evidence
TITLE: Safety of Leflunomide and Methotrexate as Combination Therapy for Rheumatoid Arthritis: A Review of the Clinical Evidence DATE: 10 May 2011 CONTEXT AND POLICY ISSUES Rheumatoid arthritis (RA) is
More informationThe CORRONA Database
The CORRONA Database J.M. Kremer Joel M. Kremer, MD, George and Jane Pfaff Professor of Medicine, Albany Medical College, Director of Research, The Center for Rheumatology, Albany, New York 12203, USA.
More informationPrimary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
More informationAppendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview. Trial duration in months
Appendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview Study Name Year Reference ABATACEPT (n=7) Moreland 2002 Moreland LW, Alten R, Van den Bosch
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationOrencia (abatacept) DRUG.00040
Market DC Orencia (abatacept) DRUG.00040 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Comments Quantity Limit Orencia (abatacept) - AGP, VA MCD only 4 vials per 28
More informationPharmacy Medical Necessity Guidelines:
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationORIGINAL ARTICLE DANIEL E. FURST, 1 AILEEN L. PANGAN, 2 LESLIE R. HARROLD, 3 HONG CHANG, 4 GEORGE REED, 3 JOEL M. KREMER, 5 AND JEFFREY D.
Arthritis Care & Research Vol. 63, No. 6, June 2011, pp 856 864 DOI 10.1002/acr.20452 2011, American College of Rheumatology ORIGINAL ARTICLE Greater Likelihood of Remission in Rheumatoid Arthritis Patients
More informationBrief Report: Identification of BACH2. and RAD51B as Rheumatoid Arthritis Susceptibility Loci in a Meta- Analysis of Genome-Wide Data
Brief Report: Identification of BACH2 and RAD51B as Rheumatoid Arthritis Susceptibility Loci in a Meta- Analysis of Genome-Wide Data The Harvard community has made this article openly available. Please
More informationEffectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry
The Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry Leslie R. Harrold, George W. Reed, Ashwini Shewade,
More informationCharacteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population
Rheumatol Ther (2015) 2:85 96 DOI 10.1007/s40744-015-0008-9 ORIGINAL RESEARCH Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationPharmacy Medical Necessity Guidelines: Orencia (abatacept)
Pharmacy Medical Necessity Guidelines: Effective: October 23, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Abatacept for the treatment of rheumatoid arthritis only after the failure of conventional disease-modifying anti-rheumatic drugs Thank you for agreeing to give us a statement on your organisation's view
More information6 ADRs, 2 LOE. 2 ADRs, 4 LOE. Ineffectiveness 24 ADRs 7, 1 pt for convenience. 48% had antibodies against Infliximab at baseline
Summary of Published Switch data Table 1. Information Patients Switch from (n) Reason for switch Switch to: (n) Results Numbers Presse Med. 2002 (1) 14 Infliximab (8) (6) 6 ADRs, 2 LOE 2 ADRs, 4 LOE (8)
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationThe GPs role with biologics for immune-mediated inflammatory diseases David Gardner Rheumatologist GPCME 2015
The GPs role with biologics for immune-mediated inflammatory diseases David Gardner Rheumatologist GPCME 2015 The views and opinions expressed in the following presentation are those of the presenter and
More information10/27/2013. Biological Insights from Genetics of Rheumatoid Arthritis Contribute to Drug Discovery. Yukinori Okada, MD, PhD.
ACR Meeting 2013, San Diego Biological Insights from Genetics of Rheumatoid Arthritis Contribute to Drug Discovery. ~ Disclosure ~ We declare no competing financial interests. Yukinori Okada, MD, PhD.
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationInfections and Biologics
Overview Infections and Biologics James Galloway What is the risk of infection with biologics? Are some patients at greater risk? Are some drugs safer? Case scenario You recently commenced Judith, a 54
More informationLOCALLY AVAILABLE BIOLOGIC AGENTS IN THE TREATMENT OF PSORIATIC ARTHRITIS
Locally Available Biologic Agents in the Treatment of Psoriatic Arthritis 253 Phil. J. Internal Medicine, 47: 253-259, Nov.-Dec., 2009 LOCALLY AVAILABLE BIOLOGIC AGENTS IN THE TREATMENT OF PSORIATIC ARTHRITIS
More informationResearch Article. Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice
Research Article Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice Aim: To evaluate treatment of rheumatoid arthritis with abatacept in the real-life clinic
More informationAmjevita (adalimumab-atto)
*- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled
More information2010 Annual Meeting of the Canadian Rheumatology Association February 3 to 6, Quebec City, Quebec. Copyright. Not for Sale or Commercial Distribution
21 Annual Meeting of the Canadian Rheumatology Association February 3 to 6, Quebec City, Quebec Copyright In February 21, Quebec City hosted the annual meeting of the Canadian Rheumatology Association
More informationThe medical treatment of rheumatoid arthritis has been dramatically improved with the
DOI: 10.5124/jkma.2010.53.10.871 pissn: 1975-8456 eissn: 2093-5951 http://jkma.org Focused Issue of This Month Medical treatment of rheumatoid arthritis (I): Nonsteroidal anti-inflammatory drugs, disease
More informationUsing subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis
Original Article DOI: 10.5152/eurjrheum.2018.17113 Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis Emily Harris 1, Bernard Ng 2 Abstract Objective: Our
More informationPharmacy Medical Necessity Guidelines: Simponi and Simponi Aria (golimumab)
Pharmacy Medical Necessity Guidelines: Simponi and Simponi Aria (golimumab) Effective: November 20, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical
More informationInflammatory arthritis, such as rheumatoid arthritis (RA), is
O r i g i n a l A r t i c l e Using Biologics in Inflammatory Arthritis: Assessing the Risks and Benefits Gina Rohekar MD FRCPC MSc (Clin Epi) About the Author Gina Rohekar is an assistant professor at
More informationEffective Health Care Program
Comparative Effectiveness Review Number 55 Effective Health Care Program Drug Therapy for Rheumatoid Arthritis in Adults: An Update Executive Summary Background Rheumatoid arthritis (RA), which affects
More informationPharmacy Medical Necessity Guidelines: Actemra (tocilizumab)
Pharmacy Medical Necessity Guidelines: Effective: July 11, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or Medical
More informationGolimumab: a novel anti-tumor necrosis factor
Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher
More informationRheumatoid Arthritis. Improving Outcomes in RA: Three Pillars. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Modern Management of Common Problems in Rheumatology: Rheumatoid Arthritis Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid
More informationQUALITY OF LIFE OF PATIENTS WITH RHEUMATOID ARTHRITIS IN BULGARIA
22 PHARMACIA, vol. 63, No. 2/2016 L. Marinov, I. Nikolova, K. Mitov, M. Kamusheva, G. Petrova QUALITY OF LIFE OF PATIENTS WITH RHEUMATOID ARTHRITIS IN BULGARIA L. Marinov 1, I. Nikolova 1, K. Mitov 2,
More informationAnnual European Congress of Rheumatology (EULAR) Madrid, Spain, June 2017
Annual European Congress of Rheumatology (EULAR) 2017 Madrid, Spain, 14-17 June 2017 NEW DATA SUGGEST NO INCREASED CANCER RISK FOR RA PATIENTS PRESCRIBED BIOLOGICAL DMARDS Reassuring findings may positively
More informationReceived: 27 May 2003 Revisions requested: 26 Jun 2003 Revisions received: 14 Aug 2003 Accepted: 19 Aug 2003 Published: 1 Oct 2003
Research article Etanercept versus etanercept plus methotrexate: a registrybased study suggesting that the combination is clinically more efficacious Ronald F van Vollenhoven 1, Sofia Ernestam 2, Anders
More informationORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab
ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents ORENCIA demonstrated comparable
More informationSummary of Risk Minimization Measures
Table 6.1.4-1: Summary of Risk Minimization Measures Safety Concern Vaccination Hepatic and renal impairment Combination therapy Elderly Routine Risk Minimization Measures Specific subsection on vaccination
More informationPragmatic and Scientific Advantages of MDHAQ/ RAPID3 Completion by All Patients at All Visits in Routine Clinical Care
S30 Pragmatic and Scientific Advantages of MDHAQ/ RAPID3 Completion by All Patients at All Visits in Routine Clinical Care Theodore Pincus, M.D., Yusuf Yazici, M.D., and Isabel Castrejón, M.D. Abstract
More informationKey words: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, treatment access
6, 21...,.,..,..,. - (RA) -,. (AS) (PsA). (Disease-modifying antirheumatic drugs, DMARDs). DMARDs 21. - RA, AS PsA. 21. RA, DMARDs. Leflunomide (Arava)., RA Methotrexate Leflunomid. DMARDs - 5 29. - RA
More information(tofacitinib) are met.
Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically
More informationAmjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65
Market DC Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2
More informationComparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
Harrold et al. Arthritis Research & Therapy (2016) 18:280 DOI 10.1186/s13075-016-1179-7 RESEARCH ARTICLE Open Access Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationOxford Inflammatory Bowel Disease MasterClass. What is early IBD? Prof. Laurent Peyrin-Biroulet Head, IBD Unit Nancy University Hospital, France
Oxford Inflammatory Bowel Disease MasterClass What is early IBD? Prof. Laurent Peyrin-Biroulet Head, IBD Unit Nancy University Hospital, France Disclosures Consulting and/or lecture fees from Merck, Abbott,
More informationIsoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
ORIGINAL ARTICLE 2017 Mar 13. [Epub ahead of print] Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
More informationNew Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab
New Evidence reports on presentations given at ACR 2009 Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab From ACR 2009: Rituximab Rituximab in combination with methotrexate
More informationSafety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis
1. Title: Safety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis 2. Background: The population of older individuals with rheumatoid arthritis
More informationNICE DECISION SUPPORT UNIT
SEQUENTIAL TNF-α INHIBITORS AND NON BIOLOGIC DMARDS ANALYSIS OF THE NATIONAL DATABANK FOR RHEUMATIC DISEASES. NICE DECISION SUPPORT UNIT Allan Wailoo School of Health and Related Research, University of
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If
More informationScottish Medicines Consortium
Scottish Medicines Consortium abatacept, 250mg powder for concentrate for solution (Orencia ) No. (400/07) Bristol Myers Squibb Pharmaceuticals Ltd 10 August 2007 The Scottish Medicines Consortium has
More informationRheumatoid Arthritis: An update for non rheumatologists
Rheumatoid Arthritis: An update for non rheumatologists Dimitrios Pappas, M.D., M.P.H. Assistant Professor of Medicine Columbia University, College of Physicians & Surgeons Director of Rheumatology Athens
More informationPharmacy Medical Necessity Guidelines: Cimzia (certolizumab pegol)
Pharmacy Medical Necessity Guidelines: Cimzia (certolizumab pegol) Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationEthnic Minority RA Consortium (EMRAC)
Ethnic Minority RA Consortium (EMRAC) Yusuf Yazıcı, MD Assistant Professor of Medicine, New York University School of Medicine Director, Seligman Center for Advanced Therapeutics & Behçet Syndrome Evaluation,
More informationBringing the clinical experience with anakinra to the patient
Rheumatology 2003;42(Suppl. 2):ii36 ii40 doi:10.1093/rheumatology/keg331, available online at www.rheumatology.oupjournals.org Bringing the clinical experience with anakinra to the patient S. B. Cohen
More informationAbatacept: first T cell co-stimulation modulator for severe active RA
Abatacept: first T cell co-stimulation modulator for severe active RA Steve Chaplin MSc, MRPharmS and Andrew Ostor FRACP PRODUCT PROFILE Proprietary name: Orencia Constituents: abatacept Dosage and method
More informationMethotrexate in Psoriatic Arthritis
S41 Methotrexate in Psoriatic Arthritis Philip Mease, M.D. Abstract Psoriatic arthritis (PsA) is a form of inflammatory arthritis that occurs in patients with psoriasis and is distinct from rheumatoid
More informationInflammation, rheumatoid arthritis and cardiovascular disease
Inflammation, rheumatoid arthritis and cardiovascular disease Yvette Meißner, Pharmacoepidemiology, German Rheumatism Research Centre www. chronische-entzuendung.org Outline I. Cardiovascular disease II.
More informationPredictors of Treatment Initiation with Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis
RESEARCH Predictors of Treatment Initiation with Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis Rishi J. Desai, PhD; Jaya K. Rao, MD; Richard A. Hansen, PhD; Gang Fang, PhD; Matthew
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationCURRICULUM VITAE PERI HICKMAN PEPMUELLER, M.D.
CURRICULUM VITAE Date: June 2012 PERI HICKMAN PEPMUELLER, M.D. Professional Address: Saint Louis University Health Sciences Center 1402 South Grand Boulevard R212 Doisy Hall St. Louis, MO 63104 Telephone
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
More informationPerformance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies
Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies 1. Introduction The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new instrument
More informationSmoking Cessation. Hassan Sajjad Pulmonary & Critical Care
Smoking Cessation Hassan Sajjad Pulmonary & Critical Care Objectives Burden of Smoking Health Impacts of Smoking Smoking Cessation Motivational Interviewing Nicotine Replacement Therapy Bupropion Varenicline
More informationTofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients
doi: 10.2169/internalmedicine.9341-17 Intern Med Advance Publication http://internmed.jp ORIGINAL ARTICLE Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve
More informationCitation for final published version:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/97756/ This is the author s version of a work that was submitted to / accepted
More informationJames R. O Dell, M.D. University of Nebraska Medical Center
Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,
More informationADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationCankaya Ortopedi. Outpatient TKA in Rheumatoid Arthritis. Prof. N. Reha Tandogan, M.D
IMUKA 2016 Transatlantic Current Concepts in Outpatient Arthroplasty Dr. N. Reha Tandoğan Outpatient TKA in Rheumatoid Arthritis Prof. N. Reha Tandogan, M.D Ortoklinik / Çankaya Orthopaedics, Ankara, Turkey
More informationComparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity
7 Comparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity Charlotte Krieckaert* Anna Jamnitski* Mike Nurmohamed Piet Kostense
More informationEtanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan
Adv Ther (2012) 29(8):691 697. DOI 10.1007/s12325-012-0039-3 ORIGINAL RESEARCH Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan Benjamin
More informationTrends in the Use of Biologic Agents Among Rheumatoid Arthritis Patients Enrolled in the US Medicare Program
Arthritis Care & Research Vol. 65, No. 11, November 2013, pp 1743 1751 DOI 10.1002/acr.22055 2013, American College of Rheumatology ORIGINAL ARTICLE Trends in the Use of Biologic Agents Among Rheumatoid
More informationPerioperative Medicine:
Perioperative Medicine: Management of rheumatologic agents Divya Gollapudi, MD May 2016 Medical Operative Consult Clinic Harborview Medical Center Your patient Ms. L is a 55 year-old F w/ h/o RA who presents
More informationPsA. SIMPONI (golimumab) Rheumatoid arthritis. Psoriatic arthritis. Ankylosing spondylitis EFFICACY EFFICACY EFFICACY. QoL. QoL.
RA Rheumatoid arthritis PsA Psoriatic arthritis AS Ankylosing spondylitis EFFICACY EFFICACY EFFICACY QoL QoL QoL SAFETY SAFETY SAFETY EXPERIENCE EXPERIENCE EXPERIENCE SUMMARY SUMMARY SUMMARY Copyright
More informationEfficacy and Safety of Etanercept in Severely Active Rheumatoid Arthritis: 6-month, Open Label, Prospective, Observational Study from Iraq
Efficacy and Safety of Etanercept in Severely Active Rheumatoid Arthritis: 6-month, Open Label, Prospective, Observational Study from Iraq Nizar Abdul Latif Jassim 1, Dalia Hassan Ibrahim 2, Faiq I. Gorial
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationSkin cancers in patients treated with immunomodulating drugs. Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France
Skin cancers in patients treated with immunomodulating drugs Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France Immunomodulating drugs used in Methotrexate Mycophenolate
More informationMETHODS In the context of an indirect comparison metaanalysis between tocilizumab and other biological
c Additional data are published online only at http://ard.bmj. com/content/vol69/issue1 Correspondence to: Professor M Boers, Department of Epidemiology and Biostatistics, VU University Medical Centre,
More informationAssessing Remission in Rheumatoid Arthritis on the Basis of Patient Reported Outcomes
136 Bulletin of the Hospital for Joint Diseases 2014;72(2):136-41 Assessing Remission in Rheumatoid Arthritis on the Basis of Patient Reported Outcomes Advantages of Using RAPID3/MDHAQ in Routine Care
More informationRheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie
1 Add your company logo here Rheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie August 13-15, 2014 AIR at UR Developing Best Practice Guidelines for Management of Rheumatoid Arthritis
More informationSynoviocytes. Macrophage. B cell C H R O N I C. Neutrophil. Mast cell I N F L A M M A T I O N. Tissue cell. Endothelial cell. Th1/Th17 IL17 IL22
DC IL12, IL23 chemokines, ECM, Co-stimulation IL17, IL22 IFNγ ± Macrophage peptidoglycan lipopolysaccharide heat shock proteins Th1/Th17 IL17 IL22 Cell contact, co-stimulation immune complexes acute phase
More informationGolimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis
Clinical Medicine Reviews in Therapeutics Review Golimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis Lauren Keyser McCluggage 1 and Kelly Michelle
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationTreatment of psoria.c arthri.s: Guidelines and beyond. Pascal RICHETTE Hôpital Lariboisière, Paris
Treatment of psoria.c arthri.s: Guidelines and beyond Pascal RICHETTE Hôpital Lariboisière, Paris The pa.ent: a 37 year- old man, with a history of psoriasis for 10 years Past history: - Dyslipidemia Current
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationUse of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United States
Arthritis Care & Research Vol. 66, No. 11, November 2014, pp 1604 1611 DOI 10.1002/acr.22383 2014, American College of Rheumatology ORIGINAL ARTICLE Use of Oral and Subcutaneous Methotrexate in Rheumatoid
More informationEffective Health Care Program
Comparative Effectiveness Review Number 28 Effective Health Care Program Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) Executive Summary Background
More informationTITLE: Biologics Dose Escalation for the Treatment of Rheumatoid Arthritis: A Review of the Clinical and Cost-Effectiveness
TITLE: Biologics Dose Escalation for the Treatment of Rheumatoid Arthritis: A Review of the Clinical and Cost-Effectiveness DATE: 22 September 2015 CONTEXT AND POLICY ISSUES Rheumatoid arthritis (RA) is
More informationOverview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology
Overview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology Paediatric Rheumatology Expert Meeting, London 4 th December 29 Dr. Richard Veselý, Dr. Emma Sala Soriano Paediatric Investigation
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationRegulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 10 Last Review Date: June 22, 2017 Humira Description Humira (adalimumab),
More informationCorporate Medical Policy
Corporate Medical Policy Rituximab for the Treatment of Rheumatoid Arthritis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: rituximab_for_the_treatment_of_rheumatoid_arthritis 4/2008
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More information